Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 4:13:857640.
doi: 10.3389/fneur.2022.857640. eCollection 2022.

Medical management of cerebral edema in large hemispheric infarcts

Affiliations
Review

Medical management of cerebral edema in large hemispheric infarcts

Grace DeHoff et al. Front Neurol. .

Abstract

Acute ischemic stroke confers a high burden of morbidity and mortality globally. Occlusion of large vessels of the anterior circulation, namely the intracranial carotid artery and middle cerebral artery, can result in large hemispheric stroke in ~8% of these patients. Edema from stroke can result in a cascade effect leading to local compression of capillary perfusion, increased stroke burden, elevated intracranial pressure, herniation and death. Mortality from large hemispheric stroke is generally high and surgical intervention may reduce mortality and improve good outcomes in select patients. For those patients who are not eligible candidates for surgical decompression either due timing, medical co-morbidities, or patient and family preferences, the mainstay of medical management for cerebral edema is hyperosmolar therapy. Other neuroprotectants for cerebral edema such as glibenclamide are under investigation. This review will discuss current guidelines and evidence for medical management of cerebral edema in large hemispheric stroke as well as discuss important neuromonitoring and critical care management targeted at reducing morbidity and mortality for these patients.

Keywords: cerebral edema; glibenclamide; hemispheric stroke; herniation; hyperosmolar.

PubMed Disclaimer

Conflict of interest statement

Author WL is a site sub-investigator in 2 Biogen studies of Glibenclamide in acute brain injury, but not the principal Investigator and does not receive direct funding from the study sponsor. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Similar articles

Cited by

References

    1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. . Heart disease and stroke statistics-2020 update: a report from the American heart association. Circulation. (2020) 141:e139–596. 10.1161/CIR.0000000000000757 - DOI - PubMed
    1. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. “Malignant” middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. (1996) 53:309–15. 10.1001/archneur.1996.00550040037012 - DOI - PubMed
    1. Vahedi K, Vicaut E, Mateo J, Kurtz A, Orabi M, Guichard J-P, et al. . Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke. (2007) 38:2506–17. 10.1161/STROKEAHA.107.485235 - DOI - PubMed
    1. Jüttler E, Schwab S, Schmiedek P, Unterberg A, Hennerici M, Woitzik J, et al. . Decompressive surgery for the treatment of malignant infarction of the middle cerebral artery (DESTINY): a randomized, controlled trial. Stroke. (2007) 38:2518–25. 10.1161/STROKEAHA.107.485649 - DOI - PubMed
    1. Hofmeijer J, Kappelle LJ, Algra A, Amelink GJ, van Gijn J, van der Worp HB, et al. . Surgical decompression for space-occupying cerebral infarction (the hemicraniectomy after middle cerebral artery infarction with life-threatening edema trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol. (2009) 8:326–33. 10.1016/S1474-4422(09)70047-X - DOI - PubMed

LinkOut - more resources